Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE10A | Q9Y233 | 3/20 | 0.39 |
| ▸ | MALT1 | Q9UDY8 | 2/20 | 0.37 |
| ▸ | TRPV1 | Q8NER1 | 2/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.35 |
| ▸ | PIM1 | P11309 | 2/20 | 0.34 |
| ▸ | GRM1 | Q13255 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2008677 | 0.83 | MALT1 (0.46) | PDE10AMALT1TRPV1KMT2APIM1 | |
| SCHEMBL4880724 | 0.80 | KDM4E (0.44) | MALT1TRPV1KMT2A | |
| SCHEMBL4778176 | 0.79 | MALT1 (0.34) | MALT1TRPV1 | |
| SCHEMBL31716179 | 0.79 | HSD11B1 (0.44) | PDE10AMALT1TRPV1KMT2A | |
| SCHEMBL18484126 | 0.79 | HSD11B1 (0.44) | PDE10AMALT1TRPV1KMT2A | |
| SCHEMBL18484125 | 0.79 | PDE10A (0.39) | PDE10AKMT2AGRM1 | |
| SCHEMBL14207437 | 0.79 | GRIN2D (0.50) | PDE10AMALT1KMT2AGRM1 | |
| SCHEMBL4880388 | 0.78 | ALDH1A1 (0.44) | PDE10AMALT1GRM1 | |
| SCHEMBL18487148 | 0.76 | PDK2 (0.39) | PDE10AKMT2AGRM1 | |
| SCHEMBL27684344 | 0.76 | MALT1 (0.48) | MALT1TRPV1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20170002016-A1 | AZASPIRO DERIVATIVES AS TRPM8 ANTAGONISTS | RAQUALIA PHARMA INC. (JP) | 2017-01-05 | — | — | US | disclosed |
| US-20170002016-A1 | AZASPIRO DERIVATIVES AS TRPM8 ANTAGONISTS | RAQUALIA PHARMA INC. (JP) | 2017-01-05 | — | — | US | disclosed |
| US-20080153850-A1 | Adamantyl Derivates as P2x7 Receptor Antagonists | ASTRAZENECA AB (SE) | 2008-06-26 | — | — | US | disclosed |
| EP-1786786-A1 | ADAMANTYL DERIVATES AS P2X7 RECEPTOR ANTAGONISTS | AstraZeneca AB (SE) | 2007-05-23 | — | — | EP | disclosed |
| WO-2006025783-A1 | ADAMANTYL DERIVATES AS P2X7 RECEPTOR ANTAGONISTS | ASTRAZENECA AB (SE) | 2006-03-09 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170002016-A1 | AZASPIRO DERIVATIVES AS TRPM8 ANTAGONISTS | TRPM8, TRPM7, TRPM5 | PDE10A 1884/4885MALT1 1975/4885TRPV1 7/4885 |
| US-20080153850-A1 | Adamantyl Derivates as P2x7 Receptor Antagonists | ADORA1, P2RX1, P2RY1 | PDE10A 1119/4885MALT1 3949/4885TRPV1 30/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.